This HTML5 document contains 137 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n11http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q49322866
rdf:type
wikibase:Item
schema:description
научни чланак vitenskapelig artikkel artigo científico 2015年学术文章 wetenschappelijk artikel bài báo khoa học artykuł naukowy artikull shkencor 2015년 논문 2015年学术文章 научная статья teaduslik artikkel 2015年學術文章 article scientifique article scientific tudományos cikk articol științific 2015年学术文章 2015 nî lūn-bûn 2015年学术文章 tieteellinen artikkeli artigo científico επιστημονικό άρθρο wissenschaftlicher Artikel artigo científico 2015年學術文章 2015年學術文章 บทความทางวิทยาศาสตร์ artículu científicu 2015年学术文章 article científic vědecký článek научна статия artículo científico publicado en 2015 artikel ilmiah 2015年学术文章 scientific article published on 23 February 2015 2015年學術文章 2015年の論文 scienca artikolo наукова стаття, опублікована в лютому 2015 ২৩ ফেব্রুয়ারি ২০১৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ naučni članak vitskapeleg artikkel articolo scientifico מאמר מדעי vetenskaplig artikel artikulong pang-agham scientific article published on 23 February 2015 мақолаи илмӣ 2015年學術文章 videnskabelig artikel vedecký článok scientific article published on 23 February 2015 სამეცნიერო სტატია مقالة علمية نشرت في 23 فبراير 2015 научни чланак bilimsel makale
p:P577
wds:Q49322866-F33F85C4-8227-44E7-A9E3-E174411B1764
wdt:P577
2015-02-23T00:00:00Z
p:P407
wds:Q49322866-2F01BAC9-C318-4DC1-B3C4-BA0691CF0888
wdt:P407
wd:Q1860
p:P2860
wds:Q49322866-1C9E44CF-1A6D-48C8-8CD5-8573A30BD2DF wds:Q49322866-C0A82D5A-5404-41EA-AB20-DEAE0AEF5A20 wds:Q49322866-C4DB8EAB-768B-41B0-A80C-E79D80CBCF8C wds:Q49322866-C987CB1F-E16C-44F3-A143-ABA8DB7B3079 wds:Q49322866-CCA9459B-C38E-4D30-80FB-07A2A620898B wds:Q49322866-881D84C4-6D81-49A2-AB15-F4D82BDCCE56 wds:Q49322866-A6E2A575-4EE2-4861-AB4A-C7EDEB162D4F wds:Q49322866-4A6BBFB1-C94E-4325-8FAB-3BDEEEDA29A8 wds:Q49322866-05050DEF-5AEB-428E-BC33-5C014AF420FE wds:Q49322866-08B261D9-9BFF-47FD-B7A8-354FE2CD4D17
wdt:P2860
wd:Q35584299 wd:Q28265610 wd:Q28131634 wd:Q33845393 wd:Q26824310 wd:Q50916927 wd:Q34149569 wd:Q35871798 wd:Q27861062 wd:Q30890582
p:P2093
wds:Q49322866-B90C06E9-D0EF-4064-9635-85BAFB782160
wdt:P2093
Caroline Robert
rdfs:label
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
skos:prefLabel
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
schema:name
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
p:P50
wds:Q49322866-1D369D98-A3D2-4368-B103-C9035A1DDBBD wds:Q49322866-0CBA0383-56F3-483D-A050-ACC29749BEC4 wds:Q49322866-554DD680-4D64-41D3-B529-B0C7F8EDFBC1 wds:Q49322866-6A7F403B-9325-4403-9679-709E990640F3 wds:Q49322866-4210B071-78E6-45B5-808B-DFB34D29AADE wds:Q49322866-FC34F268-1025-455F-8356-4A995864B65C wds:Q49322866-AAC5C96A-0910-45B2-9431-D24E37CB8972 wds:Q49322866-9B0CC5CE-53A7-46FD-A187-6D9A690A73CD wds:Q49322866-DB24D3AB-41B1-4CDC-A8FE-F375EE9D5E4B wds:Q49322866-E06B1769-83ED-4BAF-BF1D-2D7BEB9F9E03 wds:Q49322866-F5E45D40-2C73-439C-A47B-5A7E42A3874A
wdt:P50
wd:Q114522897 wd:Q88137705 wd:Q37391116 wd:Q30957829 wd:Q61182298 wd:Q80438657 wd:Q72848421 wd:Q40580858 wd:Q32649750 wd:Q56685195 wd:Q114522984
p:P1476
wds:Q49322866-F7C97B8D-8B5D-4F59-9AB2-A56A04D176E9
wdt:P1476
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
p:P304
wds:Q49322866-72256A70-D52D-4F8F-B93A-D4ACC35C9B1C
wdt:P304
1191-1196
p:P31
wds:Q49322866-B46DDB95-1754-47A3-BEC3-AC6692882822
wdt:P31
wd:Q13442814
p:P921
wds:Q49322866-FAA08257-119D-4AE2-881B-C4B03ABCCCB9 wds:Q49322866-735AEE15-4F00-4184-AA6F-BA34BA6BB013
wdt:P921
wd:Q416975 wd:Q42824827
p:P698
wds:Q49322866-35A6CA74-125E-4EA7-AAFB-AB98C629BCA4
wdtn:P698
n12:25713437
wdt:P698
25713437
p:P1433
wds:Q49322866-1F45117E-E6CD-4393-8015-06D3892B3A7F
wdt:P1433
wd:Q400292
p:P433
wds:Q49322866-398548AF-CBE2-4CB4-9B35-ACC8C879F997
p:P478
wds:Q49322866-0AB760F3-0595-4989-BE6C-257A43AED13C
wdt:P433
10
wdt:P478
33
p:P356
wds:Q49322866-29F4F1E6-997C-4A8A-99AB-C5AE3F96AE92
wdtn:P356
n11:JCO.2014.56.6018
wdt:P356
10.1200/JCO.2014.56.6018
p:P932
wds:Q49322866-95467702-B2E3-465D-AE91-47F25EA82796
wdt:P932
5795709